6:05 PM
 | 
Apr 23, 2007
 |  BC Extra  |  Financial News

Amgen meets Street EPS

AMGN reported first quarter adjusted diluted EPS of $1.08, meeting the Street consensus and up 19% from $0.91 in 1Q06. Sales were up 14% to $3.6 billion from $3.1 billion in the prior year's quarter.

First quarter sales of Aranesp for anemia were up 14% to $1 billion from $893 million in 1Q06. First-generation EPO drug Epogen had 1Q07 sales of $625 million, up 3% from $604 million in the same period...

Read the full 353 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >